Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines. [electronic resource]
Producer: 20160405Description: 1385-9 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Carcinoma, Papillary -- drug therapy
- Carcinoma, Renal Cell -- drug therapy
- Class I Phosphatidylinositol 3-Kinases
- Everolimus -- therapeutic use
- Female
- Follow-Up Studies
- Genotype
- Humans
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation -- genetics
- Neoplasm Grading
- Phosphatidylinositol 3-Kinases -- genetics
- Phosphoinositide-3 Kinase Inhibitors
- Polymerase Chain Reaction
- Prognosis
- Prospective Studies
- Protein Kinase Inhibitors -- therapeutic use
- Survival Rate
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.